About OncoGenex



OncoGenex Announces Completion of Patient Enrollment in the Phase 3 AFFINITY Trial of Custirsen in Combination with Cabazitaxel/Prednisone as Second-line Chemotherapy in Men with Metastatic Castrate-Resistant Prostate Cancer

Tuesday, Sep 16 2014

OncoGenex Announces Update on Phase 3 ENSPIRIT Trial Evaluating Custirsen in Advanced Non-Small Cell Lung Cancer

Thursday, Aug 21 2014

OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Second Quarter 2014

Thursday, Aug 7 2014

OncoGenex Pharmaceuticals Announces Appointment of John A. Bencich as Vice President and Chief Financial Officer

Thursday, Aug 7 2014

OncoGenex to Report Financial Results for Second Quarter 2014 on August 7, 2014

Thursday, Jul 24 2014

OncoGenex Announces Cedar™ Clinical Trial Evaluating Apatorsen in Combination with Chemotherapy in Advanced Squamous Cell Lung Cancer is Now Open for Enrollment

Tuesday, Jul 1 2014

OncoGenex Pharmaceuticals Announces Pricing of $24 Million Underwritten Registered Direct Offering

Thursday, Jun 26 2014


External Link Pop Up Window

You are now exiting the OncoGenex Web site and entering a third party Web site.

OncoGenex does not review the information contained on the following Web site for content, accuracy or completeness. Use of and access to the information are subject to the terms, limitations and conditions set by the Web site producer. OncoGenex makes no claims about the accuracy or any other aspect of the information contained on this Web site, nor does OncoGenex necessarily endorse this Web site.

Stay on OncoGenex Continue